Cordis Unveils Next Generation CoCr Coronary Stent

PRESILLION(TM) PLUS CoCr Coronary Stent Offers New Levels of Delivery, Support and Restoration for Arteriosclerotic Arteries

WATERLOO, Belgium, March 11, 2010 - Cordis Corporation today announced the European launch of its next
generation of bare metal stent system - PRESILLION(TM) PLUS. The new stent
system, which improves upon the ground-breaking PRESILLION(TM), features
important technological advances designed to gain easier access to distal
lesions and help restore the artery's natural form.

"The new upgraded delivery system increases the speed of procedures with
atraumatic delivery, increased pushability, and smoother withdrawal. We are
very satisfied with the speed in which we were able to incorporate feedback
from cardiologists into the new design," said Campbell Rogers MD, Global Head
of R&D of Cordis Corporation.

The PRESILLION(TM) PLUS changes include a new hypotube for improved
pushability in crossing calcified lesions and a redesigned semi-compliant
balloon for precise stent deployment and decreased deflation time.

The PRESILLION(TM) PLUS stent is available in lengths from 8 to 33mm
including a new 28mm addition and in diameters from 2.5 to 4.0mm.

The PIONIR study, designed to measure the safety and effectiveness of
PRESILLION(TM) and PRESILLION(TM) PLUS, completed enrollment at 16 sites in
Europe and Israel. The study, conducted by Medinol, includes 278 patients and
will evaluate clinical performance through one year.

"Our vision at Cordis is to transform cardiovascular care, a field in
which incredible progress has been made over the last decade, but one in
which much more remains to be done. The new PRESILLION(TM) PLUS further
complements our portfolio with its technological advances. We will continue
to deliver innovative new solutions that save lives and improve the quality
of life for people around the world," said Staffan Ternstrom, President,
Cordis Europe, Middle-East, Africa.

Cordis Corporation is the exclusive global distributor of PRESILLION(TM)
PLUS, which is designed and manufactured by Medinol Ltd, Israel. PRESILLION
(TM) PLUS is a trademark of Cordis Corporation.

About Cordis Corporation

Cordis Corporation, a Johnson & Johnson company, is a worldwide leader in
the development and manufacture of interventional vascular technology.
Through the company's innovation, research and development, Cordis partners
with interventional cardiologists worldwide to treat millions of patients who
suffer from vascular disease. More information about Cordis Corporation can
be found at www.cordis.com.

Cordis Corporation signed an exclusive distribution agreement with
Medinol in 2008 and will be distributing PRESILLION (TM) PLUS globally.
Medinol is a stent innovation company that develops both stents and delivery
systems through design innovation and advanced manufacturing technologies.

    Media Contacts: Isabella Sharp
    APCO Worldwide
    isharp@apcoworldwide.com
    +44(0)20-7526-3632
    +44(0)7813-307490

Media Contacts: Isabella Sharp, APCO Worldwide, isharp at apcoworldwide.com, +44(0)20-7526-3632, +44(0)7813-307490